long intergenic non-protein coding RNA 628Genealiases: []
Q-omics provides the consensus-scored LINC00628 profile across patient tissues and cancer cell-line models. LINC00628 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC00628 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, LINC00628 RNA expression shows 11,470 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUAD, and ESCA as cancer lineages where LINC00628 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00628 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00628 survival associations across molecular data types. LINC00628 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00628 RNA expression–survival associations across cancer types. High LINC00628 expression shows unfavorable associations in LUAD, CHOL, LUSC, ESCA, KIRP and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC00628 RNA expression.
This table summarizes LINC00628 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00628. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00628 shows higher tumor expression in LUAD, KIRC, STAD, BLCA, LIHC and COAD. The LUAD box plot shows higher LINC00628 RNA expression in tumor versus normal tissue (log2 FC = +0.298, t-test p < 0.001).
This table shows molecular features associated with LINC00628 in patient tissues and cancer cell lines. In patient samples, LINC00628 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
